Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of SR750 in Healthy Volunteers
NCT05083468Phase 1Completed
- Sponsor
- Shanghai SIMRD Biotechnology Co., Ltd.
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Peripheral neuropathic pain comparing SR750 tablet with Matching placebo (2 arms). Primary endpoint: Frequency and severity of Adverse Events (AEs). Started Oct 2021; status: completed.
02
Drugs
SR750
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on NCT05083468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083468.